期刊
RESPIRATORY RESEARCH
卷 14, 期 -, 页码 -出版社
BMC
DOI: 10.1186/1465-9921-14-55
关键词
Chronic obstructive pulmonary disease (COPD); Emphysema; Smoking; Pulmonary function testing
资金
- AstraZeneca
- GSK
- Nycomed
- Chiesi
Background: Little is known about the factors associated with CT-quantified emphysema progression in heavy smokers. The objective of this study was to investigate the effect of length of smoking cessation and clinical/demographical factors on the rate of emphysema progression and FEV1-decline in male heavy smokers. Methods: 3,670 male smokers with mean (SD) 40.8 (17.9) packyears underwent chest CT scans and pulmonary function tests at baseline and after 1 and 3 years follow-up. Smoking status (quitted >= 5, >= 1-<5, <1 years or current smoker) was noted. Rate of progression of emphysema and FEV1-decline after follow-up were assessed by analysis of variance adjusting for age, height, baseline pulmonary function and emphysema severity, packyears, years in study and respiratory symptoms. The quitted >= 5 group was used as reference. Results: Median (Q1-Q3) emphysema severity,<-950 HU, was 8.8 (5.1 - 14.1) and mean (SD) FEV1 was 3.4 (0.73) L or 98.5 (18.5) % of predicted. The group quitted '>5 years' showed significantly lower rates of progression of emphysema compared to current smokers, 1.07% and 1.12% per year, respectively (p<0.001). Current smokers had a yearly FEV1-decline of 69 ml, while subjects quit smoking >5 years had a yearly decline of 57.5 ml (p<0.001). Conclusion: Quit smoking >5 years significantly slows the rate of emphysema progression and lung function decline.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据